APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Aprea Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.53−0.05 (-8.88%)
Close on Oct 19, 2026
- Market cap
- $28.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.0377 (−66.10%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $28.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.74
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.31M
- EPS, diluted
- -$1.08
- Book value per share
- $0.72
- Diluted shares
- 53M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Operating income
-$13.22M
Net income
-$12.31M
EPS, diluted
-$1.08
Free cash flow
–
Reported periodTrailing twelve months